Saturday, 11 April 2020

VolitionRx initiates clinical trial programme in lung cancer

08 May 2019 | News

The study will be conducted under the supervision of Professor Chen Jin-Shing in the Department of Surgery of National Taiwan University

image credit- bizjournals.com

image credit- bizjournals.com

US based VolitionRx Limited has announced that it has added to its extensive clinical trial programme with the execution of a contract under the previously announced Memorandum of Understanding, to conduct its first large-scale lung cancer study in conjunction with the prestigious National Taiwan University (NTU).

The study will be conducted under the supervision of Professor Chen Jin-Shing in the Department of Surgery of NTU and will include 1,200 subjects receiving Low-Dose Computed Tomography scans, including 1,000 with lung cancer.

Volition recently announced preliminary results from two proof of concept studies utilising its first optimized product-grade assay:

  • In a lung cancer cohort (76 subjects), a single Nu.Q™ assay detected lung cancer, including stage I lung cancer. The Area Under the Curve ("AUC") for this single assay was 85%, cancer versus healthy.
  • In a second confirmatory lung cancer cohort (152 subjects), the same single Nu.Q™ assay also detected lung cancer with an AUC of 79%, cancer versus healthy.

Volition has also recently executed a nonbinding Memorandum of Understanding with Shanghai Fosun Long March Medical Science Co., Ltd. with the shared intention to enter into a binding agreement and to conduct three small-scale clinical trials in China. One of the trials is in lung cancer, and the others are in colorectal cancer and ovarian cancer, with preliminary data expected in 2019.  

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account